A lower MVPA dose than current public health guidelines (400 to <600 MET-min/wk) was associated with a reduced risk of depression.
JAMA Network Open · 4 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A lower MVPA dose than current public health guidelines (400 to <600 MET-min/wk) was associated with a reduced risk of depression.
After adjusting for multiple confounders, a negative dose-response association was observed between MVPA dose and both outcomes. The study found that an MVPA dose of 400 to less than 600 MET-min/wk was associated with a 16% lower rate of depressive symptoms and 43% lower odds of major depression. The highest activity dose (≥2400 MET-min/wk) showed the largest reductions (23% lower rate of depressive symptoms and 49% lower odds of major depression).